30 Participants Needed

Capivasertib + Abiraterone for Prostate Cancer

(SNARE Trial)

Recruiting at 4 trial locations
RP
Overseen ByRyan P Kopp, MD
Age: 18+
Sex: Male
Trial Phase: Phase 2
Sponsor: VA Office of Research and Development
Must be taking: Androgen deprivation drugs
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized prostate cancers that are most resistant to standard treatments. This is a phase II research study. For this study, capivasertib, the study drug, will be taken with intensified androgen deprivation drugs (iADT; abiraterone and leuprolide) prior to radical prostatectomy. This study drug treatment will be evaluated to see if it is effective in shrinking and destroying prostate cancer tumors prior to surgery and to further evaluate its safety prior to prostate cancer surgery.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop your current medications. However, you cannot take certain medications like potent inhibitors or inducers of CYP3A4, drugs that prolong the QT interval, or any medication that may interfere with abiraterone. It's best to discuss your current medications with the trial team to see if they are allowed.

What data supports the idea that Capivasertib + Abiraterone for Prostate Cancer is an effective drug?

The available research shows that Abiraterone, when used with prednisone, significantly improves survival in patients with advanced prostate cancer. It helps delay the progression of the disease and increases the time patients live without the cancer getting worse. In one study, Abiraterone was shown to extend survival by about four months in patients who had already received chemotherapy. This makes it a strong option for treating prostate cancer, especially when compared to a placebo, which is a treatment with no active drug.12345

What safety data is available for Capivasertib and Abiraterone in prostate cancer treatment?

Abiraterone acetate, marketed as Zytiga, is used in combination with prednisone or prednisolone for treating metastatic castration-resistant prostate cancer (CRPC). Clinical trials have shown it significantly prolongs overall survival and progression-free survival. The safety profile is generally acceptable, with common side effects including hypokalaemia, hypertension, fluid retention, cardiac events, and hepatotoxicity. The incidences of severe adverse events were relatively low in phase III studies. There is no specific safety data provided for Capivasertib in the provided research.12678

Is the drug Capivasertib + Abiraterone a promising treatment for prostate cancer?

Yes, the drug Capivasertib + Abiraterone is promising for prostate cancer. Abiraterone has been shown to significantly improve survival and delay disease progression in patients with advanced prostate cancer. It works by blocking enzymes needed for cancer growth, making it a valuable option for treating this type of cancer.12678

Research Team

RP

Ryan P Kopp, MD

Principal Investigator

VA Portland Health Care System, Portland, OR

Eligibility Criteria

Men over 18 with high-risk, non-metastatic prostate cancer that's not spread beyond the prostate and has specific genetic features (PTEN loss). They should have a life expectancy of more than 10 years, be able to take oral medication, and have no severe health issues. Men must use condoms if with a partner who can bear children. Those with active hepatitis or HIV, other cancers, significant heart disease or recent major surgery aren't eligible.

Inclusion Criteria

I am willing to give a tissue sample for testing.
I am scheduled for prostate surgery with lymph node removal.
I am a man who will use birth control when with a woman who can have children.
See 11 more

Exclusion Criteria

I have had treatments for prostate cancer, including hormone therapy, radiation, or chemotherapy.
Clinically significant abnormalities of glucose metabolism
I have not had major surgery or a serious injury recently.
See 13 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Run-in

Eligible patients undergo a 4-week run-in of intensified androgen deprivation therapy (iADT)

4 weeks

Treatment

Participants receive 16 weeks of combined iADT with AKT inhibition (capivasertib) prior to radical prostatectomy

16 weeks

Surgery

Participants undergo radical prostatectomy with assessment of pathological response

1 week

Follow-up

Participants are monitored for treatment-related adverse events and surgical complications

3 months

Treatment Details

Interventions

  • Abiraterone Acetate
  • Capivasertib
Trial OverviewThe trial is testing whether taking capivasertib along with intensified hormone therapy drugs (abiraterone acetate and leuprolide) before surgical removal of the prostate can shrink tumors in men whose cancer hasn't spread but is at high risk for progression.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment2 Interventions
neoadjuvant capivasertib combined with androgen receptor pathway therapy (leuprolide + abiraterone) prior to radical prostatectomy

Find a Clinic Near You

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials
1,691
Recruited
3,759,000+

Findings from Research

Oral abiraterone acetate (Zytiga®) significantly improves overall survival and progression-free survival in patients with metastatic castration-resistant prostate cancer (CRPC) when used with prednisone, compared to a placebo.
The treatment is specifically effective for patients who have already undergone docetaxel-containing chemotherapy, highlighting its role as a subsequent therapy in advanced prostate cancer management.
Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.Scott, LJ., Yang, LPH., Lyseng-Williamson, KA.[2021]
Abiraterone acetate is the first second-line hormonal treatment shown to improve survival in metastatic castration-resistant prostate cancer, initially approved in 2011 for patients who had not responded to docetaxel, showing a 4-month survival benefit.
The FDA has expanded its use to the pre-chemotherapy setting due to significant delays in disease progression and trends toward increased overall survival, with ongoing studies investigating its effectiveness in earlier stages and in combination with other treatments.
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.Harshman, LC., Taplin, ME.[2021]
Abiraterone acetate has been shown to significantly increase survival rates in patients with metastatic castration-resistant prostate cancer, making it a key treatment option for this condition.
Recent studies indicate that abiraterone acetate is also effective when combined with androgen deprivation therapy for metastatic castration-sensitive prostate cancer, expanding its use in earlier stages of the disease.
Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.Caffo, O., Veccia, A., Kinspergher, S., et al.[2018]

References

Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. [2021]
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. [2021]
Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. [2018]
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. [2022]
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]. [2021]
Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. [2022]
Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. [2020]
Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. [2021]